Yi-Ning Su
CEO & Managing Director
More than a decade ago, Dr Su treated a woman who had given birth to a baby with Duchenne muscular dystrophy (DMD). She felt helpless and distressed, as her husband’s family blamed her for being a carrier of the X-linked recessive genetic disorder. When she married into a new family, she was terrified at the thought of falling pregnant. At the time, medical genetic technology was relatively immature, and Dr Su could only acknowledge and share her concerns. Fortunately, the woman gave birth to a healthy girl who did not have DMD.
Dr Su decided to devote himself to genetic diagnostics and advance genetic technology in Taiwan. He founded the Laboratory of Molecular Genetic Diagnostics at National Taiwan University Hospital and worked hard to research and develop techniques, and publish clinical studies. After a decade of effort, he had achieved some robust outcomes. However, the limitations of the local healthcare environment made it difficult to implement many of his ideas.
Dr Su recruited a team of authoritative experts and medical professionals in the fields of maternal-fetal medicine, medical genetics, and clinical medicine, and founded Sofiva Genomics Co. Ltd. Our team of passionate professionals provides effective genetic testing, as well as advisory and support services, to expectant parents, patients with genetic disorders, and their families.
"Sofiva” comes from the Greek word , which means “wisdom”. This name reminds us to strive for excellence in knowledge and technology, encourages us to be moral, and represents our ongoing pursuit to improve quality of life.
We insist that all testing be completed locally by our team in Taiwan, and our laboratory has received numerous certifications.
We pride ourselves in remaining at the forefront of genomic medicine, and we ensure that the instruments and technology we use are cutting edge.
Sofiva Genomics has developed (1) a platform that can detect over 100 rare diseases and (2) diagnostic methods that can detect dozens of genetic diseases.
We aim to develop comprehensive and customized testing services that can detect various diseases from a single sample.
Sofiva Genomics has signed a cooperation agreement and developed long-term collaboration strategies with illumina®, the leading global enterprise in gene sequencing. This partnership allows us to share resources and ensures that our services remain highly competitive.
We insist that all testing be completed locally by our team in Taiwan, and our laboratory has received numerous certifications.
We pride ourselves in remaining at the forefront of genomic medicine, and we ensure that the instruments and technology we use are cutting edge.
Sofiva Genomics has developed (1) a platform that can detect over 100 rare diseases and (2) diagnostic methods that can detect dozens of genetic diseases.
We aim to develop comprehensive and customized testing services that can detect various diseases from a single sample.
Sofiva Genomics has signed a cooperation agreement and developed long-term collaboration strategies with illumina®, the leading global enterprise in gene sequencing. This partnership allows us to share resources and ensures that our services remain highly competitive.
Sofiva Genomics originated from the Laboratory of Molecular Genetics Diagnosis in the Department of Medical Genetics at National Taiwan University Hospital. With passion and a strong sense of purpose, Sofiva Genomics Ltd. was officially founded in July of 2012.
Read More+Sofiva Genomics Ltd. is founded at the National Taiwan University Innovation Incubation Center in 2012.
CEO Dr. Yi-Ning Su is interviewed on the Discovery show “BIRTH-DAYS: Science Babies”.
Comprehensive Non-invasive prenatal screening (NIPS) is completed for the first time in Taiwan.
Sofiva Genomics’clinical genomics laboratory obtains ISO 9001 certification.
Preeclampsia risk assessment screening is on the market.
Sofiva Genomics collaborates with the Taiwan Foundation for Rare Disorders and begins offering testing services for rare diseases.
Sofiva Genomics’clinical genomics laboratory receives ISO/IEC 17025 certification from TAF.
Sofiva Genomics receives Golden Torch Awards for being among the “Top Ten Enterprises with Potential” and for developing one of the “Top Ten Products with Potential”.
The Health Promotion Administration of the Ministry of Health and Welfare grants Sofiva Genomics status as a qualified domestic testing institution for genetic diseases.
Sofiva Genomics is selected as one of the rare disorder diagnosis teams by the Office of Rare Diseases Medicaid Project under the Health Promotion Administration of the Ministry of Health and Welfare.
Sofiva Genomics officially launches MyGene series screening test services.
The ROC Consumer Health and Safety Organization awards Sofiva Genomics the “Number One Brand Award”, recognizing Sofiva as an excellent enterprise.
Non-invasive prenatal screening+ (NIPS+) is launched.
Sofiva Genomics receives Golden Peak Awards for being among the “Top Ten Outstanding Enterprises” and for developing one of the “Top Ten Outstanding Products”.
Sofiva Genomics receives the Breakthrough Award from the Small and Medium Enterprise Administration of the Ministry of Economic Affairs.
Next-generation sequencing-based preimplantation genetic screening (NGS-based PGS) is launched.
Human papillomavirus (HPV) screening is on the market.
Currently, Sofiva Genomics is the only organization to offer non-invasive prenatal screening technologies patented by illumina®, the leading global enterprise in gene sequencing.
Sofiva Genomics receives the National Brand Yushan Award after being recognized as an Excellent Enterprise.
Sofiva Genomics receives the National Innovation Award for applying non-invasive prenatal screening+ techniques to prenatal testing.
Congenital cytomegalovirus infection screening test for newborns is launched.
Sofiva Genomics signs a cooperation agreement with Centre Testing International in Shanghai. The agreement outlines plans to (1) provide comprehensive technical support and (2) provide market support
Sofiva Genomics is the only genetic testing company to receive a bronze medal at the Taiwan Healthcare and Agricultural Biotech Industries Innovation Excellence Awards.
Sofiva Genomics Ltd. (stock code: 6615) officially enters the emerging market on January 5, 2017.
Fully upgrade of SOFIVA Non-Invasive Prenatal Screening (NIPS+)
Sofiva Genomics (6615) officially applies to list on OTC market on July 31, 2017.
Sofiva Genomics signs a service agreement with companies from Vietnam and Indonesia.
Sofiva Genomics cooperates with Taiwan Arts Development Association for the Disabled for Artist Calendars activities.
Sofiva Genomics (6615) officially enters the OTC market on January 22, 2018.
SOFIVA Non-Invasive Cancer Genetic Screening : SOFIVA Drug+, SOFIVA Monitor+, SOFIVA Cancer Track are launched.
Asia Cement Building: The first curtain wall building in Taiwan
SOFIVA Cancer Monitor, SOFIVA Cancer Screening are launched.
Dr. Yi-Ning Su receives the 41th Model of Entrepreneurs Awards in 2018.
Complete tests for over 1000 microdeletion syndromes and single-gene abnormalities.
Sofiva Genomics officially renames NIPS series as “SOFIVA NIPS v1.0 / v2.0 / v3.0 ”
Thailand is our first overseas location and we’ll actively expand to South East Asia market in the future.
A complete test for multiple genes screening and greatly reducing the risk of genetic diseases.
Sofiva Medical Technology Clinic is founded in Bangkok and is approved officially for specimen collection.
Sofiva Genomics receives the National Award of Outstanding SMEs for outstanding performance that can become a model to promote the transformation of SMEs.
SOFIVA Carrier Scan is awarded SNQ “ Symbol of National Quality”.
SOFIVA Non-Invasive Prenatal Screening receives an award of National Innovation awards that the achievement of biomedicine and health care fields in domestics.
SOFIVA BKK relocated to commercial district of Bangkok, surrounded by five-star hotel and office buildings. There are lots of hospitals and clinics in the same area.
SOFIVA Medical Technology Clinic is official operated on May, 2020 with clinic license.
SOFIVA Cancer Monitor and Baby Scan are awarded SNQ "Symbol of National Quality".
Sofiva Genomics respect and protects customers' privacy.
Sofiva Genomics website ("the Website or Websites") require entry of personal information and may record that information in a database when performing reservations, inquiries, member registrations and other such procedures. Sofiva Genomics and its members and Sofiva Genomics Enterprises use the information recorded to provide services beneficial to our customers. Please do not hesitate to contact us when you have further questions or inquires.
Management of personal information
The database containing the personal information of customers using the Websites is managed by designated administrators of Sofiva Genomics and contractors to Sofiva Genomics. Customers' email addresses may be used for the transmission of Sofiva Genomics's email newsletters and for email transmissions from Sofiva Genomics & Resorts members. No personal information other than the email address is disclosed for such purposes.
Customers' personal information will not be disclosed to third parties without permission.
Revision of privacy policy
Significant modifications to this privacy policy will be announced on the Website. Please refer to this privacy policy page as occasion calls for up-to-date information. Sofiva Genomics shall bear no responsibility for any discrepancies resulting from neglecting to confirm to the current policy.
Intellectual Property Rights Notice
All rights for content on Sofiva Genomics website is reserved for the cooperation, including copyright, pictures, files, information, data, website structure, and patent. The content of the website cannot be used, fixed, reproduced, broadcasted or other illegal use. Any attempt to use or quote the above content should be authorized by Sofiva Genomics, otherwise will be taken into legal procedure, the hotel reserve all legal rights.
